Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 4

The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy

Pages
416–423
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The underlying causes should beinvestigated and correctible reasons should be eliminated in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The present study aims to compare different types of insulin concerning treatment success and insulin dose requirement in type 2 diabetes patients who were receiving basal-bolus insulin therapy and to evaluate the causes of treatment failuredespite high doses of insulin.Methods: In our retrospective study, 198 type 2 diabetes patients who were receiving basal-bolus insulin therapy included.
📊
Key Findings & Data:Patients were divided into three groups according to the insulin types (Group 1: short and long-acting analogue insulin users (n=83),Group 2: short and long-acting human regular insulin users (n=58), Group 3: human regular insulin + long-acting analogue insulinusers (57)).
💡
Conclusion & Impact:The underlying causes should beinvestigated and correctible reasons should be eliminated in these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: The present study aims to compare different types of insulin concerning treatment success and insulin dose requirement in type 2 diabetes patients who were receiving basal-bolus insulin therapy and to evaluate the causes of treatment failuredespite high doses of insulin.Methods: In our retrospective study, 198 type 2 diabetes patients who were receiving basal-bolus insulin therapy included. Patients were divided into three groups according to the insulin types (Group 1: short and long-acting analogue insulin users (n=83),Group 2: short and long-acting human regular insulin users (n=58), Group 3: human regular insulin + long-acting analogue insulinusers (57)). Demographic data and daily insulin doses were recorded from the patient follow-up files. These data and the rates ofachievement of the target HbA1c levels were also compared between groups. In addition, insulin doses of the patients whoseglycemic targets could and could not be achieved were compared.Results: In this study, 123 (62.1%) of the 198 patients were female and 65 (47.9 %) were male. The mean age of the three groupswas 55.81±8.1, 58.3±8.9, 58.3±8.8, respectively. HbA1C values were 8.72±1.65% in group 1, 9.0±1.98% in group 2 and 9.05±2.24%in group 3. The rates of achievement HbA1c value below 7% were 27.7% in analogue insulin group, 25.9% human regular insulingroup and 31.6% in regular + analogue insulin group (p >0.05). There were no significant differences in daily basal and bolus insulindoses, total daily and per kg insulin doses and basal-bolus rates between groups. Higher total daily insulin doses were determinedin patients who could not achieve target glycemic values than achieved it in group 1 and 2. Higher basal insulin doses were determined in patients who could not achieve target glycemic values than could achieved it in group 3.Conclusion: In our study, in which we did not find any significant difference in the dose analysis between analogue and regularinsulin, the findings showed that high insulin doses might not be sufficient for glycemic control. The underlying causes should beinvestigated and correctible reasons should be eliminated in these patients.

🔖

Cite This Article

ÖZTÜRKMEN, Y. A., AVCI, S., ÇALIM, A., ÇETİN, E. G., DEMIR, N., MAZI, E. E., BORLU, F., ALTUNTAŞ, Y. (2020). The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 4, 416–423. https://ajindex.com/articles/364006

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Mirza R, Ishaq S, Amjad H. Transient osteoporosis of the hip. J Pak Med Assoc 2012;62:196–8
  2. Korompilias AV, Karantanas AH, Lykissas MG, Beris AE. Transient osteoporosis. J Am Acad Orthop Surg 2008;16:480–9
  3. Pande K, Aung TT, Leong JF, Bickle I. Transient Osteoporosis of the Hip: A Case Report. Malays Orthop J 2017;11:77–8
  4. Rajak R, Camilleri J. An unusual cause of hip pain. BMJ Case Rep 2011;2011:bcr0720114456
  5. Curtiss PH Jr, Kincaid WE. Transitory demineralization of the hip in pregnancy. A report of three cases. J Bone Joint Surg Am 1959;41- A:1327–33
  6. Wilson AJ, Murphy WA, Hardy DC, Totty WG. Transient osteoporosis: transient bone marrow edema? Radiology 1988;167:757–60
  7. Patel S. Primary bone marrow oedema syndromes. Rheumatol ogy (Oxford) 2014;53:785–92
  8. Cano-Marquina A, Tarín JJ, García-Pérez MÁ, Cano A. Transient regional osteoporosis. Maturitas 2014;77:324–9
  9. Szwedowski D, Nitek Z, Walecki J. Evaluation of transient osteoporosis of the hip in magnetic resonance imaging. Pol J Radiol 2014;79:36–8
  10. Asadipooya K, Graves L, Greene LW. Transient osteoporosis of the hip: review of the literature. Osteoporos Int 2017;28:1805–16
  11. Rader CP. Transient osteoporosis and osteonecrosis of the femoral head. Risk factors, classification and differential diagnosis. [Article in German]. Orthopade 2007;36:423–4, 426–9
  12. Berger CE, Kröner AH, Minai-Pour MB, Ogris E, Engel A. Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip. Bone 2003;33:346–51
  13. O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006;17:1008–12
  14. Laktasic-Zerjavic N, Curkovic B, Babic-Naglic D, Potocki K, Prutki M, Soldo-Juresa D. Transient osteoporosis of the hip in pregnancy. Successful treatment with calcitonin: a case report. [Article in German]. Z Rheumatol 2007;66:510–3
  15. Berman N, Brent H, Chang G, Honig S. Transient osteoporosis: Not just the hip to worry about. Bone Rep 2016;5:308–11.